Viruses known as “jumbo phage” are a new hope against the rising antibacterial infection crisis. Researchers have discovered how jumbo phage are able to infect bacteria so efficiently. They found a compartment that protects and hides valuable DNA material from the bacteria’s immune defense system.
A second-generation compound outperforms predecessor in the fight against coronavirus.
A powerful new software platform called the Playbook Workflow Builder is set to transform biomedical research by allowing scientists to conduct complex and customized data analyses without advanced programming skills. An article that describes the new platform was published in the April 3 online issue of the journal PLOS Computational Biology. Developed by a multi-institutional team that was led by Icahn School of Medicine at Mount Sinai investigators as part of the National Institutes of Health Common Fund Data Ecosystem (CFDE) program, researchers from across the United States developed the web-based platform that enables scientists to analyze and visualize their own data independently through an intuitive, interactive interface.
"I, Ovosan" offers inspiring cancer survivor stories interwoven with cutting-edge research, detailing the development and therapeutic potential of Ovosan's bioactive phospholipids, now available in the US as CellBB.
Nobel Laureate James Rothman, PhD; Holly A. Ingraham, PhD, FASEB’s 2024 Lifetime Achievement awardee; and George A. Brooks, PhD, FAPS, the American Physiological Society’s (APS) 2025 Walter Cannon Award recipient, are among the highlighted speakers who will attend the American Physiology Summit. The Summit, APS’ flagship annual meeting, will be held April 24–27 in Baltimore.
Together, the two organizations have created a unique alliance that blends the academic prowess of LJI with the drug development and commercialization expertise of Kyowa Kirin.
The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development. The new Center will integrate AI with traditional drug discovery methods to identify and design new small-molecule therapeutics with unprecedented speed and precision. Unlike conventional drug discovery, which can take years and cost billions, AI-driven approaches enable researchers to rapidly navigate a vast chemical landscape, including natural products, to pinpoint promising drug candidates. By leveraging Mount Sinai’s world-leading expertise in machine learning, chemical biology, and biomedical data science, the Center aims to bring innovative treatments to patients faster—particularly for diseases with urgent unmet needs, including cancer, metabolic disorders, and neurodegenerative diseases.
Exposure to antibiotics during infancy can stunt the growth of insulin-producing cells in the pancreas and may boost risk of diabetes later in life. The findings shine a light on the importance of the infant microbiome and could lead to new approaches for addressing metabolic diseases.
Recognizing their outstanding contribution to Canada or on the international stage, the medal commemorates the crowning of the former Prince of Wales in 2022.
Joseph A. Barone, dean of Rutgers Ernest Mario School of Pharmacy, was presented with the Bowl of Hygeia Award from the American Pharmacists Association and the New Jersey Pharmacists Association
Moores Cancer Center at the University of California San Diego has received a $1 million donation from pharmaceutical company Pfizer to support an innovative new program designed to bolster early cancer detection and prevention efforts. The donation will help build a bridge bringing research discoveries to community health centers and improving access to early detection tests for colorectal, breast, cervical and prostate cancer.
Engenheiros de manufatura estão na vanguarda de trazer novos medicamentos derivados de fontes humanas, como células, sangue e genes, para os pacientes. Eles produzem o que muitas vezes são bioterapias pioneiras do seu tipo para doenças que anteriormente tinham poucas ou nenhuma opção de tratamento.
Manufacturing engineers are at the forefront of bringing new medicines derived from human sources such as cells, blood and genes to patients. They produce what are often first-of-their kind biotherapies for diseases that previously had few or no treatment options.
JACKSONVILLE, Florida — Ingenieros de manufactura están a la vanguardia de llevar nuevos medicamentos derivados de fuentes humanas, como células, sangre y genes, a los pacientes. Ellos producen lo que a menudo son bioterapias pioneras de su tipo para enfermedades que anteriormente tenían pocas o ninguna opción de tratamiento.
CDI Labs Canada Inc., a leading provider of services for proteome-wide antibody profiling and target identification, today announced the launch of its Technology Access Program for custom peptide libraries for serum antibody analysis services. These services utilize phage display immunoprecipitation sequencing (PhIP-Seq), a powerful method of multiplexed analysis that combines next-generation proteomics with high-throughput DNA sequencing, to provide researchers with unparalleled insights into the intricate connection between antibodies and diseases.
جاكسونفيل، ولاية فلوريدا — يحتل مهندسو التصنيع الصدارة في جلب الأدوية الجديدة المشتقة من مصادر بشرية، مثل الخلايا والدم والجينات، للمرضى. وينتجون علاجات حيوية غالبًا ما تكون الأولى من نوعها لأمراض لم يكن لها في السابق سوى خيارات علاجية محدودة أو لم يكن لها أي خيارات.
Risk management expert Clifford Rossi warns that pharma tariffs could disrupt supply chains, raise costs, and pressure manufacturers, especially generics. Adopting continuous manufacturing offers efficiency gains, balancing risk mitigation with strategic investment.
A McMaster University team led by renowned researcher Gerry Wright has identified a strong candidate to challenge even some of the most drug-resistant bacteria on the planet: a new molecule called lariocidin.
This comprehensive review analyzes cutting-edge tools and technologies in modern pharmaceutical research, focusing on artificial intelligence, multi-omics technologies, and experimental methods. The study highlights how computational methods enhance drug discovery efficiency, while omics technologies provide systematic frameworks for investigating drug mechanisms. The integration of these advanced approaches has enabled more diverse and personalized treatment strategies, though challenges remain in drug development complexity, cost-effectiveness, and operational feasibility.
Las bases de maquillaje más oscuras suelen fallar de plano, ya que dan un aspecto grisáceo al aplicarlas sobre la piel. Pero ahora, los investigadores informan de un aditivo de color azul para cosméticos que proporciona a las bases más oscuras la calidez e intensidad de las que carecen las fórmulas actuales. Presentarán sus resultados en el encuentro de primavera de 2025 de la ACS.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right